Actuate Therapeutics And 2 Other Promising Penny Stocks To Watch

Over the last 7 days, the United States market has dropped by 1.0%, but it remains up by 11% over the past year, with earnings expected to grow annually by 17% in the coming years. For investors willing to explore beyond well-known companies, penny stocks—often representing smaller or newer enterprises—can offer intriguing opportunities. Though considered a somewhat outdated term, penny stocks still hold relevance as they can provide growth potential at lower price points when backed by strong financials and solid fundamentals.

We'll examine a selection from our screener results.

Actuate Therapeutics (ACTU)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing cancer therapies in the United States with a market cap of $18.72 million.

Operations: Actuate Therapeutics, Inc. currently does not report any revenue segments as it is a clinical-stage biopharmaceutical company focused on developing cancer therapies in the United States.

Market Cap: $18.72M

Actuate Therapeutics, Inc., with a market cap of US$18.72 million, is a pre-revenue clinical-stage biopharmaceutical company developing cancer therapies. Despite its unprofitability and high volatility, the company has managed to reduce losses by 3.3% annually over five years and maintains short-term assets exceeding liabilities. Recent preclinical data shows promising results for its drug elraglusib in combination therapies for pancreatic cancer, potentially enhancing its value proposition. However, Actuate faces challenges with Nasdaq listing compliance due to low market value of listed securities and has less than a year of cash runway based on current free cash flow trends.

• Dive into the specifics of Actuate Therapeutics here with our thorough balance sheet health report.
• Learn about Actuate Therapeutics' future growth trajectory here.

Commerce.com (CMRC)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Commerce.com, Inc. operates an artificial intelligence-driven commerce ecosystem across various regions globally with a market cap of $261.83 million.

Operations: The company generates $346.90 million in revenue from its Internet Information Providers segment.

Market Cap: $261.83M

Commerce.com, Inc. operates within the AI-driven commerce ecosystem with a market cap of US$261.83 million, generating significant revenue from its Internet Information Providers segment. Recent announcements include new product capabilities like Feedonomics Enrichment and BigCommerce Catalog Enrichment, enhancing merchants' product data for AI-powered discovery. Despite unprofitability and high volatility, the company has reduced losses significantly over five years and maintains a solid cash runway exceeding three years due to positive free cash flow growth. The firm also initiated a US$50 million share repurchase program funded through disciplined capital allocation strategies, reflecting confidence in its financial stability.

• Navigate through the intricacies of Commerce.com with our comprehensive balance sheet health report here.
• Explore Commerce.com's analyst forecasts in our growth report.

Butler National (BUKS)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Butler National Corporation is involved in the design, engineering, manufacturing, sales, integration, installation, repair, modification, overhaul, servicing, and distribution of aerostructures and aircraft components with a market cap of $256.96 million.

Operations: The company's revenue is derived from four main segments: Gaming ($37.61 million), Aircraft Avionics ($3.27 million), Aircraft Modifications ($47.85 million), and Special Mission Electronics ($19.89 million).

Market Cap: $256.96M

Butler National Corporation, with a market cap of US$256.96 million, has demonstrated strong financial performance, reporting annual revenue of US$97.97 million and net income of US$21.93 million for the fiscal year ending April 30, 2026. The company’s earnings have grown significantly over the past year by 68.1%, outpacing its five-year average growth rate and surpassing industry benchmarks in Aerospace & Defense. Its robust balance sheet is highlighted by short-term assets exceeding liabilities and a debt level well-covered by cash flow, while recent share buybacks reflect strategic capital management. However, the board's relatively short tenure may indicate limited experience at leadership levels.

• Unlock comprehensive insights into our analysis of Butler National stock in this financial health report.
• Examine Butler National's past performance report to understand how it has performed in prior years.

Seize The Opportunity

• Jump into our full catalog of 315 US Penny Stocks here.
• Interested In Other Possibilities? Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com